JB Chemicals & Pharmaceuticals has emerged in a new avatar as JB, retaining its core value of being ‘Good people for good health’. The company announced its new identity at a media meet recently.

In sync with the evolving healthcare industry and the changing need of customers, JB has re-visioned the cause of spreading good health in India. JB aims to support healthcare providers and enrich patients’ lives in innovative new ways while remaining committed to its core values of integrity, trust and reliability built over 45 years.

 Announcing the change of identity to JB – Good People for Good Health, Nikhil Chopra, CEO & Whole-time Director, JB, said, “In 45 years, we at JB have built a strong foundation of integrity, trust and reliability. Now we are taking the next leap forward towards becoming more agile, lean and simple. Our offerings and capabilities are becoming more diverse to cater to the evolving needs of our customers, our manufacturing processes are becoming more robust, and lean, and our vision of looking at the healthcare industry is becoming more progressive globally. We are adapting ourselves to become more responsive to the needs of the healthcare world.”

Adding further, Chopra said, “While we are changing in many ways, we are not changing the solid foundation of JB. Our new identity has a simple, solid look that reflects the way, we think and conduct ourselves. It is a symbol of our belief in being ‘Good People for Good Health’.”

Speaking on JB’s financial achievements, Chopra said, “Because of our consistent performance, we have maintained the sales momentum in the fourth quarter of FY-2021-22, closing it on a positive note in the face of the challenging external environment. Our domestic business has also maintained its stellar performance with its double-digit growth, and we continue to retain our position as the fastest-growing company in Indian Pharmaceutical Industry (IPM) amongst the top 30.”

In the financial year 2021-22, the company recorded revenue of INR 2,424 crore as compared to INR 2,043 crore in FY 2020-21, registering a growth of 19%. The sales growth for the last quarter was 18% and domestic formulations continued their market-beating performance, recording a growth of 30%.

According to MAT Mar’ 2022, JB grew at 29% versus market growth of 18%; and as per the last quarter of Financial Year 2022, it grew at 21% versus market growth of 10%. Also, 6 new products were launched in the last quarter of Financial Year 2022, with over 15-key new launches excluding product line extensions.

JB’s international business has also bounced back in the fourth quarter of Financial Year 2021-22, witnessing double-digit growth across segments with a growth rate of 9% YoY. A strong surge driven by the Contract Manufacturing business in South Africa and APIs has been recorded.

Catering to the evolving needs of customers (patients), JB has been adapting to the emerging new technologies and acquiring the leading pharma brands. The recent acquisition of Sanzyme has helped JB gain ranks and figures in the top-30 brands of the Indian Pharmaceutical Market (IPM). Likewise, by the acquisition of Azmarda in April 2022, JB is likely to surge more ranks in the Indian Pharmaceutical Market.

JB has emerged as the fastest growing Indian Pharmaceutical company. It has figured among the top 30 pharma companies in the IPM with a remarkable growth rate of 19% in the Financial Year 2021-22. The five household brands of JB have featured in the top 300 of IPM with 4 brands (including Azmarda) in the top 100 in the cardiac therapy segment. JB currently ranks at 12 in the gastrointestinal segment in IPM. It has over 350 brands with 20 key therapeutic categories. Its brands are available across 600,000 pharmacies in India in almost every PIN code.

The 5 household brands of JB featured in the top 300 of the Indian Pharmaceutical Market (IPM) are – Rantac (anti-ulcerate) with IPM rank at 45 and gastro-intestinal segment rank at 6; Cilacar (anti-hypertensive) with rank at 52 and cardiac segment rank at 4; Cilacar-T (anti-hypertensive) with rank at 203 and cardiac segment rank at 22; Metrogyl (amoebicide) with IPM rank at 194; Nicardia (anti-hypertensive) with rank at 240 and cardiac segment rank at 30.